Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (23 quarters reported)
$1.1B in Q4 2020 → $88.1M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Surrozen, Inc. | 56.5% | Unchanged | 1,916,950 | $49.7M |
| Oric Pharmaceuticals Inc. | 43.5% | Unchanged | 3,540,777 | $38.3M |
| Revolution Medicines Inc | 0.0% | Unchanged | 46 | $8.62K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
No position changes this quarter.
quarter ended March 31, 2026 · filed May 18, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Tenaya Therapeutics, Inc. | Exited | −9,400,290 | −$6.69M | — |
| Rapt Therapeutics Inc | Exited | −156,270 | −$5.29M | — |
| Surrozen, Inc. | Added | +65,600 | +$1.91M | 55.4% |
quarter ended December 31, 2025 · filed February 13, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Surrozen, Inc. | Added | +351,577 | +$7.95M | 50.5% |
| Rapt Therapeutics Inc | Trimmed | −9,805 | −$332K | 6.4% |
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Rapt Therapeutics Inc | Trimmed | −1,162,538 | −$30M | 5.3% |
quarter ended June 30, 2025 · filed August 15, 2025
No position changes this quarter.
quarter ended March 31, 2025 · filed May 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Surrozen, Inc. | Added | +689,685 | +$8.04M | 39.5% |
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Rapt Therapeutics Inc | Trimmed | −1,352,008 | −$2.14M | 3.8% |
| Sagimet Biosciences Inc. | Exited | −17,169 | −$47.6K | — |
quarter ended September 30, 2024 · filed November 14, 2024
No position changes this quarter.
Loading...
